ORIC Plans Global Phase 3 Redwood-1 Trial Of Enozertinib In 1L EGFR Atypical NSCLC In 1H 2027 After Phase 1b Showing 84% Confirmed Systemic ORR, 70% Confirmed Intracranial ORR
Benzinga·10/23/2026 07:17:44
语音播报
- In a 1L EGFR atypical population with more than double the rate of baseline CNS metastases as competitor datasets, enozertinib demonstrates a potential best-in-class 84% confirmed systemic ORR and 70% confirmed intracranial ORR, with multiple intracranial complete responses
- 88% 6-month landmark PFS compares favorably to current standards of care and to investigational therapies; follow-up ongoing with majority of patients continuing on treatment
- Competitive safety profile with no significant off-target toxicity and no treatment-related discontinuations
- Redwood-1 global Phase 3 registrational trial initiation in 1L EGFR atypical NSCLC expected in 1H 2027